The roles of IL-10 and IL-4 receptor signaling were evaluated in a murine model of Leishmania major infection. In previous studies the L. major substrain LV39 caused progressive, nonhealing lesions in BALB/c mice deficient for IL-4R alpha-chain (IL-4R alpha), while substrain IR173 was highly controlled. To explore whether IL-10 is responsible for inducing susceptibility to LV39, wild-type and IL-4R alpha(-/-) mice were treated with anti-IL-10R mAb, and in a genetic approach, the IL-4R alpha(-/-) mice were crossed with BALB/c IL-10(-/-) mice. In contrast to the lack of resistance conferred by IL-4R alpha gene deletion, partial resistance to LV39 was conferred by IL-10 gene deletion or treatment of BALB/c mice with anti-IL-10R mAb. Lesion sizes and LV39 parasite numbers were further and dramatically reduced in both anti-IL-10R-treated IL-4R alpha(-/-) mice and IL-4R alpha x IL-10 double knockouts. Anti-IL-10R mAb treatment further suppressed parasite growth in IL-4R alpha(-/-) mice infected with L. major IR173. Production of IFN-gamma was only increased relative to wild-type or littermate controls in IL-4R alpha(-/-) mice with complementary defects in IL-10. Comparisons of IFN-gamma-treated infected macrophages in vitro indicated that LV39 required 25- to 500-fold greater concentrations of IFN-gamma than IR173-infected macrophages to achieve a similar efficiency of parasite killing. These studies suggest that regardless of parasite substrain, IL-10 is as important as IL-4/IL-13 in promoting susceptibility to L. major and even more so for those substrains that are relatively resistant to IFN-gamma mediated killing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4049/jimmunol.170.10.5152 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic literature review on early clinical evidence for immune-resolution therapies and potential benefits to patients and healthcare providers.
Front Immunol
November 2024
Eli Lilly and Company, Indianapolis, IN, United States.
Article Synopsis
- - Current treatments for autoimmune diseases often fail to achieve long-term remission, prompting interest in therapies that restore balance in the immune system, known as immune resolution; however, there's no clear consensus on how to evaluate these therapies in clinical trials.
- - A systematic literature review (SLR) was conducted using established guidelines to explore expert opinions and previous studies on immune resolution in five autoimmune diseases: asthma, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, and ulcerative colitis; this involved searching databases and conference proceedings from 2013 to 2023.
- - The SLR included 26 publications and found that expert opinions tended to lack specific measures for assessing immune resolution but suggested potential targets and biomarkers for future therapy
Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody.
Int Immunopharmacol
December 2024
Qyuns Therapeutics Co., Ltd., Taizhou, Jiangsu, China. Electronic address:
Article Synopsis
- Severe asthma is a chronic condition that current treatments struggle to manage, and Thymic stromal lymphopoietin (TSLP) plays a crucial role in its development, indicating the potential of blocking TSLP for treatment.
- The study developed a new humanized anti-TSLP antibody called QX008N, which showed high efficacy in stopping TSLP-induced inflammation and improved lung function in animal models when used alone and in combination with anti-IL-4R antibodies.
- The findings suggest that targeting both TSLP and IL-4R pathways may offer a more effective treatment strategy for asthma, providing strong preclinical support for these combination therapies.
A multifunctional antibody fusion protein 57103 targeting CD24, IL-4R, and αβ for treating cancer and regulating the tumor microenvironment.
Biomed Pharmacother
June 2024
State Key Laboratory of Natural Medicines, Ministry of Education, the Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province, Department of Marine Pharmacy, China Pharmaceutical University, Nanjing 211198, China; The Engineering Research Center of Synthetic Peptide Drug Discovery and Evaluation of Jiangsu Province, China Pharmaceutical University, Nanjing 210009, China. Electronic address:
Article Synopsis
- Cancer ranks as one of the deadliest diseases globally, with advanced metastatic carcinoma leading in mortality, highlighting the urgent need for new targeted therapies.
- Researchers developed a novel antibody fusion protein, 57103, which effectively targets multiple receptors and exhibited significant anti-cancer effects in vitro by suppressing the growth, migration, and invasion of renal cancer cells.
- In animal studies, 57103 demonstrated the ability to inhibit tumor growth and promote cancer cell death while also improving immune responses, indicating its potential as a treatment for metastatic renal carcinoma or other cancers that overexpress PDL1.
CD44v5 domain regulates crosstalk between TNBC cells and tumor-associated macrophages by enhancing the IL-4R/STAT3 axis.
Cancer Sci
July 2024
Department of Clinical Laboratory, The 4th Hospital of Harbin Medical University, Harbin, China.
Article Synopsis
- Triple-negative breast cancer (TNBC) is associated with high levels of M2-like macrophages (TAMs), which worsen cancer progression and prognosis.
- CD44v5 is highly expressed in TNBC cells and plays a crucial role in promoting metastasis by interacting with IL4Rα, activating the STAT3/IL6 signaling pathway and influencing TAM polarization.
- Targeting the CD44v5 domain could be a potential strategy for regulating the tumor microenvironment and developing treatments for TNBC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!